重大事件
即時報告
8-K
2026-07-29
Inhibikase Therapeutics 與 RA Capital 簽訂換股協議，發行預先注資權證
AI 繁中摘要
📄 **申報類型：8-K（即時報告）**
**公司：Inhibikase Therapeutics, Inc.（納斯達克代碼：IKT）**
**報告日期：2026年7月29日**
🔹 **重點事件：與RA Capital簽訂換股協議**
Inhibikase Therapeutics 於2026年7月29日與主要股東 RA Capital Healthcare Fund, L.P. 簽訂換股協議。RA Capital 將持有的 **18,030,000 股普通股**（每股面值$0.001）交回公司，換取一份 **預先注資權證（Pre-Funded Warrant）**，該權證可按每股 **$0.001** 的行使價認購同等數量的普通股（即18,030,000股）。
🔹 **權證主要條款**
- 即時可行使，**無到期日**
- 設有**實益擁有權限制**：行使後持有人（連同關聯方）不可持有超過公司已發行股份總數的 **9.99%**（持有人可於61天前通知，將此上限提高至最多 **19.99%**）
- 權證的行使價及可發行股份數量會因股份分拆、合併等公司事件而調整
🔹 **發行依據**
是次權證發行**毋須向SEC註冊**，依賴《1933年證券法》第 **3(a)(9)** 條的豁免（屬於現有股東交換證券，不涉及現金募集）。
🔹 **對投資者的潛在影響**
- **稀釋效應**：雖然RA Capital即時交回普通股，令已發行股本暫時減少，但權證若被行使，將重新增加相同數量的普通股，未來或對每股盈利及投票權造成稀釋。
- **資本結構靈活性**：RA Capital透過權證保留未來持股彈性，有助維持其長期支持意願，但9.99%的實益擁有權限制亦限制短線集中持股風險。
- 此交易屬非公開協商，對二級市場價格的直接影響有限，惟投資者須留意潛在的攤薄時間點。
🔹 **文件附件**
公司同時提交了權證範本（Exhibit 4.1）及XBRL互動數據封面頁。
**總結**：Inhibikase 透過與RA Capital換股，將既有普通股轉為預先注資權證，短期內減少已發行股份，但保留未來可轉換的稀釋風險。此舉或為優化股東結構或為後續融資鋪路，投資者應關注權證行使動態。
展開英文正文
8-K false 0001750149 0001750149 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2026 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39676 26-3407249 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1000 N. West Street, Suite 1200 Wilmington, DE 19801 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (302) 295-3800 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 3.02. Unregistered Sales of Equity Securities. On July 29, 2026, we entered into an exchange agreement with RA Capital Healthcare Fund, L.P., or RA Capital, pursuant to which RA Capital exchanged 18,030,000 shares of our common stock, par value $0.001 per share, or common stock, for a pre-funded warrant to acquire 18,030,000 shares of our common stock. The pre-funded warrant has an exercise price of $0.001 per underlying share of common stock, are immediately exercisable and have no expiration date. The number of shares of our common stock issuable upon exercise of the pre-funded warrant is subject to adjustment upon certain corporate events, including certain stock dividends and splits, combinations and other similar transactions. The pre-funded warrant includes a beneficial ownership blocker that provides that the holder may not exercise (nor may we allow the exercise) if upon giving effect to such exercise, it would cause the aggregate number of shares of our common stock beneficially owned by the holder (together with affiliates and any other persons whose beneficial ownership of our common stock would be aggregated for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended) to exceed 9.99% of the total number of then issued and outstanding shares of our common stock as determined in accordance with the terms of the pre-funded warrant. This threshold may be increased or decreased upon 61 days’ prior notice at the discretion of the holder, but not in excess of 19.99%. We issued the pre-funded warrant without registration in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The form of pre-funded warrant is filed as Exhibit 4.1 hereto and is incorporated herein by reference. The foregoing description does not purport to be complete and is qualified in its entirety by reference to such exhibit. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Pre-Funded Warrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 29, 2026 INHIBIKASE THERAPEUTICS, INC. By: /s/ Mark Iwicki Mark Iwicki Chief Executive Officer